MSD DPP-4 inhibitor doesn’t increase CV risk in diabetes, heart patients

Sigma trials diabetes pilot; index finger with pinprick of blood as in diabetes testing
small drop of blood on the tip of a finger

A major study of 14,671 patients from 38 countries with type 2 diabetes and established cardiovascular disease has found that a DPP-4 inhibitor does not increase the risk for major adverse CV events, hospitalisation for heart failure or adverse events.

This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Register here

Forgot Password?

Previous Guild member fees slashed by 25% for a year
Next Colorectal cancer treatment shows benefit

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.